Yuly A. Remolina-Bonilla, MD

Articles by Yuly A. Remolina-Bonilla, MD

Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma

ByFrancisco J. Castro-Alonso, MD,Evelyn Beas-Lozano, MD,Yuly A. Remolina-Bonilla, MD,Thomas W. Flaig, MD,María T. Bourlon, MD, MSc, FASCO

June 23rd 2023

Francisco Castro-Alonso, MD, and colleagues describe the effects of the use of erdafitinib in a patient with metastatic urothelial bladder cancer.

Sjögren Syndrome Induced by Immune Checkpoint Inhibitors in a Patient with Advanced Renal Cell Carcinoma

ByEmilio Conde-Flores, MD,Yuly A. Remolina-Bonilla, MD,Francisco J. Castro-Alonso, MD,Nayeli A. Martínez-Ibarra, MS,Gabriela Hernández-Molina, MD,Mónica Chapa-Ibargüengoitia, MD,Armando Gamboa-Domínguez, MD,María T. Bourlon, MD, MSc, FASCO

August 14th 2021

This clinical quandary details a Mexican man, aged 77 years, who presented to the oncology clinic with a sternal mass. Based on the results, the patient fulfilled the 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for Sjögren syndrome, thus the diagnosis triggered by immune checkpoint inhibitors was definitively established.

Challenges of Treating a Patient With Advanced Prostate Cancer During the COVID-19 Pandemic

ByLucia Carril-Ajuria, MD,Yuly A. Remolina-Bonilla, MD,Alberto Carretero-Gonzalez, MD,Maricruz Martin-Soberon, MD,Daniel Castellano, MD,Christianne Bourlon, MD, MHSc,Guillermo de Velasco, MD, PhD,María T. Bourlon, MD, MSc, FASCO

August 12th 2020

Immune-Related Adverse Events Involving Multiple Organ Sites in a Patient Treated With Nivolumab Plus Ipilimumab

ByYuly A. Remolina-Bonilla, MD,Brenda Jimenez-Franco, MD,María T. Bourlon, MD, MSc, FASCO,Elaine T. Lam, MD

May 13th 2020

Experts discuss the case of a 56-year-old white man who presents with multiple immune-related adverse events

What Are Treatment Options After Progression in PDL-1–Positive Metastatic Lung Adenocarcinoma after Chemo/IO?

ByYuly A. Remolina-Bonilla, MD,Raul R. Trejo-Rosales, MD,Bruno Saldivar-Oviedo,Alejandro Gabutti, MD,María T. Bourlon, MD, MSc, FASCO

August 23rd 2019

What is the best treatment option after progression to chemotherapy/immunotherapy (chemo/IO) as first-line treatment for PD-L1–positive lung adenocarcinoma with no sensitizing mutations?

Yuly A. Remolina-Bonilla, MD

Articles by Yuly A. Remolina-Bonilla, MD

Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma

Sjögren Syndrome Induced by Immune Checkpoint Inhibitors in a Patient with Advanced Renal Cell Carcinoma

Challenges of Treating a Patient With Advanced Prostate Cancer During the COVID-19 Pandemic

Immune-Related Adverse Events Involving Multiple Organ Sites in a Patient Treated With Nivolumab Plus Ipilimumab

What Are Treatment Options After Progression in PDL-1–Positive Metastatic Lung Adenocarcinoma after Chemo/IO?

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

Achieving a “Functional Cure” With Multiple Myeloma Therapy

FDA Accepts sNDA for Taletrectinib in ROS1-Positive NSCLC